. Mean somatic mutation allele frequency for any somatic variants in a 1MB window centered on key genes as a function of purity corrected copy number levels.
A B 2 C D The fact that the deletion level is not at -1 reflects the fraction of tumor clones carrying the deletion. The mean mutant allele frequency also depends on wether the mutation predates the acquisition of a deletion by a sample. The curves in red denotes the fit of Equation 2 to the mutations in samples with deletion copy number, and the blue lines are fit using leave-one-out cross-validation subsets. (A) BRCA1 (F=0.63 ,p=0.007), (B) BRCA2 (F=0.98, p=0.125), (C) TP53 (F=0.62, p=0.01), (D) TP53 deleterious mutations only (F=1.10).
Figure S2. Differentially expressed gene signature for HR defect.
Genes differentially expressed between HR deficient cell lines and HR competent cells lines (Peng et al., 2014) . Since the signature was derived from gene expression microarrays, Panel a only included genes in the top fifty percent of variance/median ratio in sequencing and expected log2ratio of |log2|>0.5 between the two categories. 
Figure S4. Technical validation of copy number in aCGH.
Comparison of aCGH results for early versus late TCGA, as technical validation of TCGA focal amplification/deletions that has significant differences between the early stage HGS (Mayo or TCGA as determined by SNP arrays) and the TCGA late stage HGS samples. The most significant region, containing the PRIM2 gene, has increased frequency of copy number loss in the late stage samples. Figure S5 . Schematic of tumor evolution.
Mean mutant allele frequency ~
Mean mutant allele frequency < purity-corrected copy number frequency purity-corrected copy number frequency (A) Early mutation in a cancer gene, followed by the loss of a normal copy, will lead to higher mutant allele frequency relative to fraction of copy number loss. (B) Late mutation in cancer gene, subsequent to copy number loss, lead to lower fraction of chromosomes carrying the deleted mutation. Figure S6 . Genome-wide LOH and prevalence.
The bottom blue line shows the relative number of samples with LOH. Samples are ordered according to the clustering as shown in Figure S7 .
Figure S7. Clustered genome-wide LOH.
Heatmap is made by dividing each chromosome in 100 segments and assigning 0 if no LOH and 2 if an LOH. Dendrogram is computed using hiearchical clustering with default setting of the heatmap command in R. Yellow denotes regions with LOH. Megabase sequenced and % coverage refer to regions with at least 10X coverage; mean coverage represents average coverage calculated by dividing the total bases sequenced with the size of haploid human genome. Computationally estimated tumor purity (percentage tumor cells in sample) estimated based on mutant allele frequency. Generally, the estimates are a lower than the pathology estimates, perhaps due to the presence of subclones or false positive variants; bold indicates high estimated ploidy (>3.5). Number of types of mutations (reverse-Complement mutations merged); C->T transitions dominate and T->G are suppressed; bold indicates most and least frequent mutation type per sample. Table S10 . Recurrent genes in SV
